NCT07793968Active, not recruiting
Point of Care NT-proBNP Testing for Suspected New Heart Failure Acute Care
Evaluating the Effectiveness and Implementation of Point-of-Care NT-proBNP Testing in Acute Care for Patients With Newly Suspected Heart Failure: A Hybrid Effectiveness-Implementation Study
Source: ClinicalTrials.gov · Last updated 31 Aug 2026
Brief summary (registry, in English)
Heart failure is a serious condition that can be difficult to diagnose quickly when patients present to hospital with symptoms such as breathlessness. Delays in diagnosis may delay treatment and adversely affect patient outcomes. N-terminal pro-B-type natriuretic peptide (NT-proBNP) is a blood biomarker recommended in national and international guidelines to support the diagnosis of heart failure. Conventional laboratory testing can take several hours before results are available. This study will evaluate the use of point-of-care NT-proBNP testing, which provides results at the bedside within approximately 12 minutes, in patients presenting to hospital with suspected new heart failure. The study will compare time to heart failure diagnosis, time to treatment initiation, length of hospital stay, 30-day hospital readmission, and 30-day mortality between patients receiving point-of-care NT-proBNP testing and a retrospective comparison cohort managed before its introduction. In addition, healthcare professionals involved in delivering the service will complete a questionnaire to evaluate the acceptability and feasibility of implementing point-of-care NT-proBNP testing within routine clinical practice. The findings will help determine the clinical and operational impact of point-of-care NT-proBNP testing and inform future service development and research in heart failure care.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 252 (actual)
- First submitted
- 13 Mar 2026
- Start date
- 30 Apr 2024
- Primary completion date
- 31 Mar 2026
- Lead sponsor
- University of Stirling
- Diseases
- Heart failure
- NCT number
- NCT07793968
What you commit to
- Study type: Interventional
- Participants enrolled: 252
- From 30 Apr 2024 to the primary completion date, 31 Mar 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous or existing clinical diagnosis of heart failure
Other illness
- Acute myocardial infarction at presentation
Age
- Aged less than 18 years
Other
- Lacks capacity to provide informed consent
Who the study is looking for
- Aged 18 years or older
- Presenting with new suspected heart failure
- Presenting with unexplained breathlessness suggestive of heart failure
- Able to provide written informed consent
- Has capacity to consent to study participation
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University Hospital Crosshouse Coordinator of this site? Confirm its status | Kilmarnock | United Kingdom | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.